China’s Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) announced receiving clinical approval from the National Medical Products Administration (NMPA) for its Category 2.2 drug AD108. This modified version of Japan-based Nichi-Iko Pharmaceutical Co., Ltd’s kallidinogenase is designed to improve neurological deficits caused by acute ischemic stroke (AIS).
Drug Mechanism and Development
AD108’s active ingredient is human urinary kininogenase, also known as tissue kallikrein 1 (KLK1), a serine protease secreted by the kidneys. It works through the kallikrein-kinin system (KKS) and interacts with the renin-angiotensin system (RAS) to maintain circulatory system stability. This subcutaneous administration method allows the drug to maintain steady-state blood concentration, ensuring continuous therapeutic effects while avoiding the blood pressure drop risk associated with intravenous administration.
Clinical Significance
The approval marks a significant step forward in the treatment of acute ischemic stroke, offering a novel approach to address neurological deficits. AD108’s unique mechanism and administration route position it as a potential breakthrough in stroke therapy, with the potential to improve patient outcomes and reduce the burden of this debilitating condition.-Fineline Info & Tech
